Zorini, A.O. (1957) Pyrazinamide. Indian Journal of Tuberculosis, 5 (1). pp. 20-31.
Full text available as:
The Author reports on a series of clinical and biological investigations on Pyrazinamide and Cycloserine carried on in the “Carlo Forlaninni” Institute of Rome in the therapy of tuberculosis. These investigations are concerned with the peripheral hematologic picture, the serum electrophoretic picture, phagocytosis, the thyroid function examination through the dosage of precipitable bound iodine, the cortico-suprarenal function examination, the behavior of specific proteases of defence in urine, of the plasma lypasic power, of cholesterolemia, of bilrubinemia, of the plasma fibrinogen, of prothrombin time, of the serolability tests and of the changes in liver functions. Pyrazinamide has shown a favourable action on tuberculous lesions in a limited number of cases and for a short duration time, not exceeding usually 35-40 days therapy ; after time, toxic phenomena are seen specially on liver function. Also biological tests tend to worsen after this period with an increase of the precipitable bound iodine and a dissociation between beta globulins, that tend to increase and gamma globulina that appreciably decrease. Cycloserine is a more powerful antibiotic acting in a favourable way, also on chronic cavitary forms resistant to other already known antibiotics and producing in a good percentage of cases, regression of far advanced cavtiaties and disappearing of tubercle bacilli from the expectoration. Its toxic action on central nervous system is not frequent and commonly does not disturb the therapy continuation. However the post mortem finding of congestion of the brain has to be reckond with Biological tests generally gave a favourable answer even during the second and third month of therapy : the precipitiable bound iodine, the seroprotoins picture and particularly beta and gamma globulins, the plasma fibringen, the prothrombin time, the plasma lypasic power, the specific proteases of defence in urine and the liver function tests have presented a behavior opposite to that observed in the case of Pyrazinamide therapy.
Archive Staff Only: edit this record